MOSES technology better than conventional holmium laser enucleation in BHP: study
MOSES technology gave better results as compared to the conventional holmium laser enucleation of the prostate, for patients suffering from benign prostatic hyperplasia proposes a study published in The Journal of Urology.
Benign prostatic hyperplasia (BPH) also referred to as enlargement of the prostate gland is a very common condition, generally affecting older men. It is characterized by urinary symptoms, like obstructing the flow of urine and it may also cause bladder, urinary tract, or kidney issues. There are several effective treatments for prostate gland enlargement, however, holmium laser enucleation is one of the most common and safe interventional surgery performed. But the new laser technology, the MOSES™ pulse laser system may further improve the efficacy of the traditional holmium laser enucleation of the prostate.
A study was conducted by a group of researchers working at the Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, to assess the efficacy of holmium laser enucleation of the prostate using MOSES technology.
The researchers conducted a single-center, prospective, double-blind, randomized controlled trial on a total of 60 patients. Patients were equally divided into two groups (one group was operated with traditional holmium laser enucleation while the other using MOSES technology) and they were randomized in a ratio of 1:1. Primarily, the difference in the operative time between both groups was studied. While, the secondary endpoints focussed on enucleation, morcellation, hemostasis duration, amount of blood loss, functional outcomes, and any adverse events after 6 weeks.
The findings were as follows:
- The operative time for the holmium laser enucleation of the prostate using MOSES technology group was shorter as compared to the other group (mean: 101 vs. 126 minutes, p <0.01).
- Also, the holmium laser enucleation of the prostate using MOSES technology group had shorter enucleation duration (mean: 68 vs. 80 minutes, p=0.03), and hemostasis duration (mean: 18 vs. 29 minutes, p <0.01)
- Additionally, the holmium laser enucleation of the prostate using MOSES technology group demonstrated less blood loss (mean: −6.3 vs. −9.0%, p=0.03)
- However, no difference in functional or safety outcomes at follow-up was observed between both the groups.
The researchers concluded that the usage of MOSES technology resulted in a better operative time, improved enucleation and hemostasis times as well as reduced blood loss when compared to the traditional holmium laser enucleation of the prostate.
A study titled, "MOSES™ Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Controlled Trial" by Kavoussi, N et. al published in The Journal of Urology.